Next Article in Journal
Perinatal Exposure to Triclosan Results in Abnormal Brain Development and Behavior in Mice
Previous Article in Journal
From the Argonauts Mythological Sailors to the Argonautes RNA-Silencing Navigators: Their Emerging Roles in Human-Cell Pathologies
Article

A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-β Signaling and Activation of cAMP/PKA Signaling

1
Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
2
Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
3
Department of Cell Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Kraków, Poland
4
Department of Pharmacokinetics and Physical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
5
Department of Molecular Pharmacology, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(11), 4008; https://doi.org/10.3390/ijms21114008
Received: 11 May 2020 / Revised: 30 May 2020 / Accepted: 31 May 2020 / Published: 3 June 2020
(This article belongs to the Section Molecular Pharmacology)
Phosphodiesterase (PDE) inhibitors are currently a widespread and extensively studied group of anti-inflammatory and anti-fibrotic compounds which may find use in the treatment of numerous lung diseases, including asthma and chronic obstructive pulmonary disease. Several PDE inhibitors are currently in clinical development, and some of them, e.g., roflumilast, are already recommended for clinical use. Due to numerous reports indicating that elevated intracellular cAMP levels may contribute to the alleviation of inflammation and airway fibrosis, new and effective PDE inhibitors are constantly being sought. Recently, a group of 7,8-disubstituted purine-2,6-dione derivatives, representing a novel and prominent pan-PDE inhibitors has been synthesized. Some of them were reported to modulate transient receptor potential ankyrin 1 (TRPA1) ion channels as well. In this study, we investigated the effect of selected derivatives (832—a pan-PDE inhibitor, 869—a TRPA1 modulator, and 145—a pan-PDE inhibitor and a weak TRPA1 modulator) on cellular responses related to airway remodeling using MRC-5 human lung fibroblasts. Compound 145 exerted the most considerable effect in limiting fibroblast to myofibroblasts transition (FMT) as well as proliferation, migration, and contraction. The effect of this compound appeared to depend mainly on its strong PDE inhibitory properties, and not on its effects on TRPA1 modulation. The strong anti-remodeling effects of 145 required activation of the cAMP/protein kinase A (PKA)/cAMP response element-binding protein (CREB) pathway leading to inhibition of transforming growth factor type β1 (TGF-β1) and Smad-dependent signaling in MRC-5 cells. These data suggest that the TGF-β pathway is a major target for PDE inhibitors leading to inhibitory effects on cell responses involved in airway remodeling. These potent, pan-PDE inhibitors from the group of 7,8-disubstituted purine-2,6-dione derivatives, thus represent promising anti-remodeling drug candidates for further research. View Full-Text
Keywords: asthma; COPD; myofibroblasts; airway remodeling; fibroblast-to-myofibroblast transition; TGF-β; phosphodiesterases; cAMP; TRPA1 channels; calcium influx asthma; COPD; myofibroblasts; airway remodeling; fibroblast-to-myofibroblast transition; TGF-β; phosphodiesterases; cAMP; TRPA1 channels; calcium influx
Show Figures

Graphical abstract

MDPI and ACS Style

Wójcik-Pszczoła, K.; Chłoń-Rzepa, G.; Jankowska, A.; Ślusarczyk, M.; Ferdek, P.E.; Kusiak, A.A.; Świerczek, A.; Pociecha, K.; Koczurkiewicz-Adamczyk, P.; Wyska, E.; Pękala, E.; Gosens, R. A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-β Signaling and Activation of cAMP/PKA Signaling. Int. J. Mol. Sci. 2020, 21, 4008. https://doi.org/10.3390/ijms21114008

AMA Style

Wójcik-Pszczoła K, Chłoń-Rzepa G, Jankowska A, Ślusarczyk M, Ferdek PE, Kusiak AA, Świerczek A, Pociecha K, Koczurkiewicz-Adamczyk P, Wyska E, Pękala E, Gosens R. A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-β Signaling and Activation of cAMP/PKA Signaling. International Journal of Molecular Sciences. 2020; 21(11):4008. https://doi.org/10.3390/ijms21114008

Chicago/Turabian Style

Wójcik-Pszczoła, Katarzyna; Chłoń-Rzepa, Grażyna; Jankowska, Agnieszka; Ślusarczyk, Marietta; Ferdek, Paweł E.; Kusiak, Agnieszka A.; Świerczek, Artur; Pociecha, Krzysztof; Koczurkiewicz-Adamczyk, Paulina; Wyska, Elżbieta; Pękala, Elżbieta; Gosens, Reinoud. 2020. "A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-β Signaling and Activation of cAMP/PKA Signaling" Int. J. Mol. Sci. 21, no. 11: 4008. https://doi.org/10.3390/ijms21114008

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop